Related Experiment Video
Updated: Sep 25, 2025

07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.3K
Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer
Bilal A Siddiqui1, Sumit K Subudhi1, Padmanee Sharma2
1Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cell Reports. Medicine
|May 2, 2022
Abstract:
The addition of atezolizumab (anti-PD-L1) to enzalutamide (androgen receptor antagonist) did not prolong survival in metastatic prostate cancer.1 Efficacy with immunotherapies in prostate cancer will require additional studies to elucidate and target mechanisms of resistance within the prostate tumor microenvironment.

